---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072594"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:16:48.361896+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS

## Summary
- 9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.
- RAINIER Cohort 2 fully enrolled; Cohort 3 now open; 5/6 patients in Cohort 1 achieved remission within 30 days.
- No cytokine release syndrome observed in ongoing RAINIER trial; favorable safety profile attributed to ADAPTIR format.
- Financial results for Q1 2025 reported but no specific figures disclosed in this release.

## SEC filing metadata
- accession: 0000950170-25-072594
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/0000950170-25-072594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/apvo-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072594
- JSON: https://secwatch.observer/filing/0000950170-25-072594.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.